Clinical Trials · NCT04551495
Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- Jules Bordet Institute
- Enrollment
- 65
- Start date
- Jan 2021
- Locations
- 10 sites, Belgium, France
- Primary endpoint
- Evaluation of the efficacy of endocrine therapy + entrectinib in women with ER+/HER2- early breast cancer of the lobular subtype:Residual Cancer Burden (RCB)